GBT Reports Fourth Quarter and 2018 Results

Friday, March 22, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Company Alignment on Long-term Strategic Agenda and Investment on Operation and Execution

MONTEVIDEO, Uruguay, March 22, 2019 /PRNewswire/ -- Biotoscana Investments S.A. (B3: GBIO33), a biopharmaceutical group

that operates in Latin America, announced today its results for the 4Q18 and 2018.

HIGHLIGHTS

Net revenues for 2018 increased by 10% in constant currency, positively impacted by Dosa, marking BRL 821M (including hyperinflation adjustment).

Gross profit increased by 12% vs. 2017, in constant currency. Gross margin of 51% (including hyperinflation adjustments) vs. 54% in 2017.

OPEX are in line with 34% of net revenues in 2018.

Adjusted EBITDA increased by 12% in constant currency vs. 2017. Adjusted EBITDA margin came to 22% in 2018 (including hyperinflation adjustment), vs. 24% in 2017.

Net income totaled BRL 63M in 2018 (including hyperinflation adjustment) vs. BRL 17M in 2017. Adjusted net income up 42% vs. 2017, in constant currency.

Strategic agenda evolved with the ongoing execution of the pipeline.

Recently launched products growing over 100%, with the performance of new products such as LENVIMA, ABRAXANE and Gilead portfolio.

Contacts:Melissa Angeliniir@grupobiotoscana.com +55 11 5090-5927.

Cision View original content:http://www.prnewswire.com/news-releases/gbt-reports-fourth-quarter-and-2018-results-300816985.html

SOURCE Biotoscana Investments S.A



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store